Hepatic failure in a patient with rheumatoid arthritis treated with methotrexate: A case report. 2023

Masayuki Miyata, and Sho Ishiwata, and Masahito Kuroda, and Kazuhiro Tasaki, and Kiyoshi Migita, and Hiromasa Ohira
Center for Rheumatology and Collagen Diseases, Fukushima Red Cross Hospital, Fukushima, Japan.

BACKGROUND Chronic liver damage from methotrexate (MTX) is not uncommon, and fatal outcome is rare. We experienced a case of hepatic failure leading to death. We considered the cause of death through this case and proposed a method to prevent the progression of this liver injury. METHODS We report the case of a patient with rheumatoid arthritis treated with MTX for 15 years. METHODS A liver biopsy revealed histological changes similar to those of advanced nonalcoholic steatohepatitis (NASH), most likely induced by MTX. MTX was discontinued after 4 years. Two years after the discontinuation, the patient died of irreversible hepatic failure. Her obesity, complicated by type 2 diabetes mellitus, might have aggravated MTX-induced NASH-like liver injury. CONCLUSIONS Early diagnosis and immediate MTX discontinuation following NASH diagnosis and strict type 2 diabetes mellitus control might have prevented the irreversible progression of liver injury.

UI MeSH Term Description Entries
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis
D017093 Liver Failure Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed) Hepatic Failure
D018501 Antirheumatic Agents Drugs that are used to treat RHEUMATOID ARTHRITIS. Anti-Rheumatic Agent,Anti-Rheumatic Drug,Antirheumatic Agent,Antirheumatic Disease-Modifying Second-Line Drug,Antirheumatic Drug,DMARD,Disease-Modifying Antirheumatic Drug,Disease-Modifying Antirheumatic Drugs,Anti-Rheumatic Agents,Anti-Rheumatic Agents, Non-Steroidal,Anti-Rheumatic Drugs,Antirheumatic Disease-Modifying Second-Line Drugs,Antirheumatic Drugs,Antirheumatic Drugs, Disease-Modifying,Disease-Modifying, Antirheumatic Second-Line Drugs,Agent, Anti-Rheumatic,Agent, Antirheumatic,Anti Rheumatic Agent,Anti Rheumatic Agents,Anti Rheumatic Agents, Non Steroidal,Anti Rheumatic Drug,Anti Rheumatic Drugs,Antirheumatic Disease Modifying Second Line Drug,Antirheumatic Disease Modifying Second Line Drugs,Antirheumatic Drug, Disease-Modifying,Antirheumatic Drugs, Disease Modifying,Disease Modifying Antirheumatic Drug,Disease Modifying Antirheumatic Drugs,Disease Modifying, Antirheumatic Second Line Drugs,Drug, Anti-Rheumatic,Drug, Antirheumatic,Drug, Disease-Modifying Antirheumatic,Non-Steroidal Anti-Rheumatic Agents
D065626 Non-alcoholic Fatty Liver Disease Fatty liver finding without excessive ALCOHOL CONSUMPTION. Fatty Liver, Nonalcoholic,NAFLD,Nonalcoholic Fatty Liver Disease,Nonalcoholic Steatohepatitis,Fatty Livers, Nonalcoholic,Liver, Nonalcoholic Fatty,Livers, Nonalcoholic Fatty,Non alcoholic Fatty Liver Disease,Nonalcoholic Fatty Liver,Nonalcoholic Fatty Livers,Nonalcoholic Steatohepatitides,Steatohepatitides, Nonalcoholic,Steatohepatitis, Nonalcoholic

Related Publications

Masayuki Miyata, and Sho Ishiwata, and Masahito Kuroda, and Kazuhiro Tasaki, and Kiyoshi Migita, and Hiromasa Ohira
January 2014, Case reports in hematology,
Masayuki Miyata, and Sho Ishiwata, and Masahito Kuroda, and Kazuhiro Tasaki, and Kiyoshi Migita, and Hiromasa Ohira
January 2006, Reumatismo,
Masayuki Miyata, and Sho Ishiwata, and Masahito Kuroda, and Kazuhiro Tasaki, and Kiyoshi Migita, and Hiromasa Ohira
March 2015, BMC research notes,
Masayuki Miyata, and Sho Ishiwata, and Masahito Kuroda, and Kazuhiro Tasaki, and Kiyoshi Migita, and Hiromasa Ohira
July 2000, The Journal of rheumatology,
Masayuki Miyata, and Sho Ishiwata, and Masahito Kuroda, and Kazuhiro Tasaki, and Kiyoshi Migita, and Hiromasa Ohira
January 2020, BMJ case reports,
Masayuki Miyata, and Sho Ishiwata, and Masahito Kuroda, and Kazuhiro Tasaki, and Kiyoshi Migita, and Hiromasa Ohira
January 2012, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases,
Masayuki Miyata, and Sho Ishiwata, and Masahito Kuroda, and Kazuhiro Tasaki, and Kiyoshi Migita, and Hiromasa Ohira
July 2009, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,
Masayuki Miyata, and Sho Ishiwata, and Masahito Kuroda, and Kazuhiro Tasaki, and Kiyoshi Migita, and Hiromasa Ohira
October 2022, The American journal of tropical medicine and hygiene,
Masayuki Miyata, and Sho Ishiwata, and Masahito Kuroda, and Kazuhiro Tasaki, and Kiyoshi Migita, and Hiromasa Ohira
January 2019, Reumatologia clinica,
Masayuki Miyata, and Sho Ishiwata, and Masahito Kuroda, and Kazuhiro Tasaki, and Kiyoshi Migita, and Hiromasa Ohira
January 2015, Internal medicine (Tokyo, Japan),
Copied contents to your clipboard!